Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 21, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 23, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001683168-26-003163
Filed / recorded
Apr 23, 2026, 9:00 PM UTC
Added to OQRO
Oct 8, 2026, 2:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Xenetic Biosciences, Inc.
Issuer CIK
1534525
Ticker
XBIO
Reporting person
James F Parslow
Relationship
Officer
Officer title
Interim CEO and CFO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Apr 21, 2026
Transaction code
A
Shares / units
100,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
100,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.